Rocket Pharmaceuticals (STU:9IP1) Current Accrued Expense : €23.46 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Current Accrued Expense?

Rocket Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2025 was €23.46 Mil.

Rocket Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2024 (€24.16 Mil) to Dec. 2024 (€24.72 Mil) but then declined from Dec. 2024 (€24.72 Mil) to Mar. 2025 (€23.46 Mil).

Rocket Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2022 (€24.60 Mil) to Dec. 2023 (€20.84 Mil) but then increased from Dec. 2023 (€20.84 Mil) to Dec. 2024 (€24.72 Mil).

Rocket Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Rocket Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Current Accrued Expense Chart

Rocket Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

16.45

12.82

24.60

20.84

24.72

Rocket Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															23.82	25.49	24.16	24.72	23.46

Rocket Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Rocket Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Rocket Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (STU:9IP1) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

RCKT:USA

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals Headlines

No Headlines